10-K: Amarin Reports Fiscal Year 2024 Results, Navigates Generic Competition and Expands Global Reach

Amarin Corporation reports its 2024 financial results, highlighting challenges from U.S. generic competition and progress in European and international markets.

Summary

• Amarin Corporation plc reported its financial results for the fiscal year ended December 31, 2024.
• The company is focused on commercializing and developing therapeutics to improve cardiovascular health, with its primary product being VASCEPA (icosapent ethyl).
• VASCEPA has received regulatory approval for reducing cardiovascular risk in high-risk patients in multiple countries, including the U.S. and EU member states.
• The company faces significant competition from generic versions of icosapent ethyl in the U.S., which has negatively impacted revenue.
• Amarin is expanding its commercial operations in Europe and other international markets through partnerships and direct sales efforts.
• The company implemented an Organizational Restructuring Program (ORP) in July 2023, resulting in the elimination of the U.S. sales force and a 30% reduction in the employee base, leading to $50 million in annual cost savings.
• The company's net loss for 2024 was $82.2 million, compared to a net loss of $59.1 million in 2023.
• As of December 31, 2024, Amarin had cash and short-term investments totaling $294.2 million.
• The company is pursuing regulatory approvals for VASCEPA in additional countries and regions to expand its global market presence.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in international markets and cost-saving measures, the financial results are negatively impacted by generic competition and increased net losses.

Positives

• VASCEPA has received regulatory approval in 49 countries, including the U.S. and 27 EU member states.
• The company is actively expanding its commercial operations in Europe and other international markets.
• The Organizational Restructuring Program (ORP) is expected to result in $50 million in annual cost savings.
• VASCEPA has the benefit of data protection afforded through Health Canada until the end of 2027, in addition to separate patent protection with expiration dates that could extend into 2039.
• In April 2024, a patent was issued that extended exclusivity in Europe to 2039.
• More than 50 clinical treatment guidelines, consensus statements, or scientific statements from global medical societies or journals have recognized the use of icosapent ethyl, or IPE, in appropriate at-risk patients for CV risk reductions.

Negatives

• The company faces significant competition from generic versions of icosapent ethyl in the U.S.
• The company's net loss for 2024 was $82.2 million, an increase from $59.1 million in 2023.
• The company has limited experience commercializing VASCEPA outside the U.S.
• The company is seeking relevant pricing approvals in various countries; however, we may not be successful in obtaining such approvals in a timely manner, or at all and even if successfully obtained, we may not be successful in commercializing VAZKEPA in major markets outside the United States.

Risks

• The company is substantially dependent on VASCEPA and its commercialization.
• Increasing competition from generic drug companies in the U.S. could materially and adversely affect revenues and results.
• The company may not be successful in obtaining pricing approvals or commercializing VAZKEPA in major markets outside the U.S.
• Factors outside of the company's control may make it more difficult for VASCEPA to achieve market acceptance.
• The company's supply of product is dependent on third-party manufacturers and suppliers.
• The company is dependent on patents, proprietary rights, and confidentiality obligations to protect the commercial value of VASCEPA.
• The company is currently, and in the future may be, party to litigation and government investigations.
• The company has a history of operating losses and may not be able to generate significant revenue to achieve steady profitability.
• The company's efforts to return capital to shareholders may not be implemented in a timely manner or have the expected results.
• If the company is unable to meet the listing requirements of the NASDAQ Stock Market, its stock may be delisted.

Future Outlook

The company will continue to focus on getting VASCEPA to as many patients as possible by continuing to advance its pricing and reimbursement and licensing activities to drive access in remaining geographies as well as being the market leader in the U.S.

Management Comments

• The Board of Directors appointed Aaron Berg, previously our Executive Vice President, President U.S., to succeed Mr. Holt as our President and Chief Executive Officer, and as a member of the Board of Directors.
• Effective December 13, 2024, our Vice President, Global Controller and principal financial and accounting officer of the Company, Peter Fishman, has been appointed as Senior Vice President, Chief Financial Officer.

Industry Context

The biotechnology and pharmaceutical industries are highly competitive, with many companies actively engaged in the research and development of similar products. The company faces competition from large pharmaceutical companies, generic manufacturers, and dietary supplement providers.

Comparison to Industry Standards

• The document mentions competitors such as Woodward Pharma Services LLC (Lovaza), AbbVie, Inc. (Tricor, Trilipix, Niaspan), and AstraZeneca (failed STRENGTH trial with Epanova).
• The document references the JELIS study in Japan, which showed that Epadel (ethyl-EPA) reduced cardiovascular events by 19% compared to statins alone.
• The document notes that recent CV outcomes trials with low and high dose omega-3 fatty acid mixtures containing DHA have not shown substantial benefit in patients receiving contemporary medical therapy, including statins.

Management Changes

Legal Proceedings

• The company is involved in several ongoing legal proceedings, including patent litigation and antitrust claims.
• The company is cooperating with government agencies in ongoing investigations.

Stakeholder Impact

• Shareholders: The company's financial performance and stock price are affected by generic competition and ongoing litigation.
• Employees: The Organizational Restructuring Program (ORP) resulted in a reduction of the employee base.
• Patients: The availability and affordability of VASCEPA may be affected by pricing and reimbursement decisions in different markets.

Next Steps

• Continue to advance pricing and reimbursement activities to drive access in remaining geographies.
• Assess other potential partnership opportunities for VASCEPA with companies outside of the U.S. and Europe.
• Continue to monitor the bid price for our ADS and considering available options to resolve the deficiency.

Key Dates